Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
about
CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration in HIV-infected patientsDose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit allEfavirenz and the CNS: what we already know and questions that need to be answeredInfluence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patientsInterindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system.Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.In vitro analysis and quantitative prediction of efavirenz inhibition of eight cytochrome P450 (CYP) enzymes: major effects on CYPs 2B6, 2C8, 2C9 and 2C19Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.Expanding the Antimalarial Drug Arsenal-Now, But How?Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylationDrug interactions and antiretroviral drug monitoring.Metabolic drug-drug interaction potential of macrolactin A and 7-O-succinyl macrolactin A assessed by evaluating cytochrome P450 inhibition and induction and UDP-glucuronosyltransferase inhibition in vitro.Enantiomer selective glucuronidation of the non-steroidal pure anti-androgen bicalutamide by human liver and kidney: role of the human UDP-glucuronosyltransferase (UGT)1A9 enzymeUse of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz.Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populationsPharmacogenomics of antimicrobial agents.UGT genomic diversity: beyond gene duplication.Chemokine (C-C motif) receptor 5 -2459 genotype in patients receiving highly active antiretroviral therapy: race-specific influence on virologic successModest but variable effect of rifampin on steady-state plasma pharmacokinetics of efavirenz in healthy African-American and Caucasian volunteersAntimalarial pharmacology and therapeutics of atovaquoneQuantitative profiling of human renal UDP-glucuronosyltransferases and glucuronidation activity: a comparison of normal and tumoral kidney tissuesPopulation pharmacogenetic-based pharmacokinetic modeling of efavirenz, 7-hydroxy- and 8-hydroxyefavirenz.PharmGKB summary: Efavirenz pathway, pharmacokineticsUse of antineoplastic agents in patients with cancer who have HIV/AIDS.Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.Individualization of antiretroviral therapy.Induction of CYP2C19 and CYP3A activity following repeated administration of efavirenz in healthy volunteers.Impact of efavirenz on intestinal metabolism and transport: insights from an interaction study with ezetimibe in healthy volunteers.Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.CYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.Neuronal toxicity of efavirenz: a systematic review.Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients.Pharmacogenetics of antiretroviral therapy.Transcriptional regulation of human UDP-glucuronosyltransferase genes.Pharmacogenetics of CYP2B6, CYP2A6 and UGT2B7 in HIV treatment in African populations: focus on efavirenz and nevirapine.Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluation.
P2860
Q24606937-C676305D-1867-46CC-9822-CC00FACF2520Q24609011-A81869D0-3718-484D-B9EC-90E77EB0E47FQ28085028-4BF2A25F-50BB-431B-8410-CE95DD146A19Q28293875-FFBBDE66-55CB-4A18-A24B-BFE2BFACDDDAQ33451969-94C71675-7AF7-4CEF-B392-BE00DA2EC3E5Q33798516-2C495B02-067A-4F70-9EF4-CDE44A4778E7Q33821729-E7ED3B4E-B858-4CEC-95CA-D7910C73140AQ33909996-3A8A6B12-477A-4D95-BDAD-70AEDE1137BAQ33916111-9CE38F37-6786-4CDB-BA1A-168500B0426AQ34015667-F39D66EE-9B3D-4E8F-A832-F53779A437F1Q34021173-F6BA8342-4FD0-4C11-8955-FE9041F4B234Q34057508-A6FF4906-F108-47FB-A7B0-93254587E881Q34335228-09672B0D-76EB-4F6F-8C55-758141D58D90Q34503553-8A6FB65D-AD38-402D-A171-5514E843B16EQ34737523-47062E28-1645-4E04-905B-E4E7AD823920Q34826590-F6CB5825-DF37-4D93-8DD9-B6D03B5CB8A5Q34977413-81DEA956-E148-4DC2-B4C2-47976FE28F73Q35009521-2F668AD6-BEFF-4EDC-8818-0887D262F49AQ35043700-5039D8C3-FBEC-4110-A458-1EA4BC577A42Q35065867-6300A18F-8F73-4DBC-B398-3855787A3F16Q35131253-07F11052-2CF6-4567-B845-908D4E73228DQ35197861-6D23585C-C6B8-4F8D-8D51-B75FF09B6111Q35547723-08C00858-0C36-4573-93EC-C3F6181540CEQ35706069-27B08BA3-ED04-4FE1-A218-6D756612995BQ35932561-BDD8CE12-B0CA-4EE5-A34B-CF4B3C30F3C5Q36079108-9F04CC26-E2CD-4EDC-A40A-DB5B2C44E661Q36441423-E377B3A2-A92F-4E59-8CC5-12AD16181CCBQ36887128-493804A9-EC2B-402F-A7EA-F84E94AB2169Q36887174-EFCBA6F7-E58F-45A3-86A1-1C09EE4BA3BCQ37086418-A1B63ED9-F770-47A4-BED3-67CA8ACE770BQ37325589-C912C2EA-EBD8-409D-BF2D-61289C72BFD6Q37358704-A957A7FC-CA71-403F-8B9E-149C1A3856E6Q37429325-03A7AB15-3680-4F92-94B0-B36D4B709B3DQ37538760-79AED859-1E17-42E6-8C43-4C8E771818D7Q38124394-0186C35B-8373-4EFE-B39F-759711E2A601Q38164430-6ACD5DF2-A047-468D-A363-2780A413E2BEQ38221179-D106D567-BA60-42FC-97E0-D15C24E4993EQ38261875-96573D8F-987F-43DD-AF34-5E35830019F7Q38267710-107F3B55-8CE9-4426-A853-0EE11F634238Q38324557-AD6FDEF9-EA0E-40A8-9E0B-709135A2AD13
P2860
Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Glucuronidation of the antiret ...... g interaction with zidovudine.
@en
type
label
Glucuronidation of the antiret ...... g interaction with zidovudine.
@en
prefLabel
Glucuronidation of the antiret ...... g interaction with zidovudine.
@en
P2093
P2860
P356
P1476
Glucuronidation of the antiret ...... g interaction with zidovudine.
@en
P2093
Anne-Sophie Bélanger
Mario Harvey
Patrick Caron
Rajeev K Mehlotra
P2860
P304
P356
10.1124/DMD.109.027706
P577
2009-06-01T00:00:00Z